Cargando…

The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer

BACKGROUND: The epidermal growth factor receptor (EGFR) is a potential target of anticancer therapy in gastric cancer. However, its prognostic role in metastatic gastric or gastroesophageal junction (GE) cancer has not been established yet. METHODS: EGFR status was analyzed by immunohistochemistry (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Atmaca, Akin, Werner, Dominique, Pauligk, Claudia, Steinmetz, Kristina, Wirtz, Ralph, Altmannsberger, Hans-Michael, Jäger, Elke, Al-Batran, Salah-Eddin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529672/ https://www.ncbi.nlm.nih.gov/pubmed/23153332 http://dx.doi.org/10.1186/1471-2407-12-524

Ejemplares similares

Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma
por: Werner, Dominique, et al.
Publicado: (2013)

SNAI2/SLUG and estrogen receptor mRNA expression are inversely correlated and prognostic of patient outcome in metastatic non-small cell lung cancer
por: Atmaca, Akin, et al.
Publicado: (2015)

The validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testing
por: Werner, Dominique, et al.
Publicado: (2014)

VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
por: Thomaidis, Thomas, et al.
Publicado: (2014)

Perspectives on the Management of Oligometastatic Disease in Esophago-Gastric Cancer
por: Goetze, Thorsten Oliver, et al.
Publicado: (2022)

Correction: Phase I clinical study of the recombinant antibody-toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas
por: von Minckwitz, Gunter, et al.
Publicado: (2006)

Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas
por: von Minckwitz, Gunter, et al.
Publicado: (2005)

Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2‐Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
por: Al‐Batran, Salah‐Eddin, et al.
Publicado: (2020)

A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer
por: Atmaca, A, et al.
Publicado: (2013)

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors
por: Haense, N., et al.
Publicado: (2016)

RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV
por: Lorenzen, Sylvie, et al.
Publicado: (2020)

Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer
por: Lorenzen, S, et al.
Publicado: (2013)

Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma – the phase III “PREVENT”- (FLOT9) trial of the AIO /CAOGI /ACO
por: Götze, Thorsten O., et al.
Publicado: (2021)

Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) – a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)– the AIO/ CALGP/ ACO- GAIN-trial –
por: Goetze, Thorsten O., et al.
Publicado: (2020)

Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials
por: Al-Batran, S-E, et al.
Publicado: (2010)

Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415)
por: Lorenzen, Sylvie, et al.
Publicado: (2023)

Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma
por: Lordick, Florian, et al.
Publicado: (2021)

Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer
por: Karbach, Julia, et al.
Publicado: (2023)

AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer
por: Kripp, Melanie, et al.
Publicado: (2017)

Multimodal Treatment Strategies in Esophagogastric Junction Cancer: a Western Perspective
por: Goetze, Thorsten Oliver, et al.
Publicado: (2019)

A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study
por: Harbeck, Nadia, et al.
Publicado: (2016)

The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial
por: Al-Batran, S-E, et al.
Publicado: (2006)

Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review
por: Chiorean, Elena Gabriela, et al.
Publicado: (2019)

HER2 testing in gastric cancer: results of a German expert meeting
por: Lordick, Florian, et al.
Publicado: (2017)

Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)
por: Tintelnot, Joseph, et al.
Publicado: (2020)

Prognostic significance of metastatic lymph node ratio in gastric cancer: a Western-center analysis
por: Ergenç, Muhammer, et al.
Publicado: (2023)

Sarcopenia as a prognostic factor for survival in patients with locally advanced gastroesophageal adenocarcinoma
por: Koch, Christine, et al.
Publicado: (2019)

Metastatic myxoid liposarcoma of the brain: a case report and review of the literature
por: Muhsen, Baha'eddin A, et al.
Publicado: (2021)

Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data
por: Fuchs, Charles S., et al.
Publicado: (2017)

Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial
por: Atmaca, A, et al.
Publicado: (2007)

Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer
por: Adashek, Jacob J., et al.
Publicado: (2020)

Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer
por: Knödler, Maren, et al.
Publicado: (2018)

Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)
por: Modest, Dominik Paul, et al.
Publicado: (2017)

Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
por: Catenacci, Daniel V., et al.
Publicado: (2021)

NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma
por: Liu, Zhenjiang, et al.
Publicado: (2017)

Cytokine Networks and Survivin Peptide-Specific Cellular Immune Responses Predict Improved Survival in Patients With Glioblastoma Multiforme
por: Zhenjiang, Liu, et al.
Publicado: (2018)

Identification of prognostic factors and surgical indications for metastatic gastric cancer
por: Mohri, Yasuhiko, et al.
Publicado: (2014)

Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma
por: Ma, Lucy X., et al.
Publicado: (2020)

Effect of epidermal growth factor receptor status on the outcomes of patients with metastatic gastric cancer: A pilot study
por: AYDIN, K., et al.
Publicado: (2014)

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
por: Le, Dung T., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hstrk83oo5sb0ahnfcmaoeo55r